<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311414752</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311414752</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Physiological regulation of extracellular matrix collagen and elastin in the arterial wall of rats by noradrenergic tone and angiotensin II</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Dab</surname><given-names>Houcine</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311414752">1</xref>
<xref ref-type="aff" rid="aff2-1470320311414752">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kacem</surname><given-names>Kamel</given-names></name>
<xref ref-type="aff" rid="aff2-1470320311414752">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hachani</surname><given-names>Rafik</given-names></name>
<xref ref-type="aff" rid="aff2-1470320311414752">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dhaouadi</surname><given-names>Nadra</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311414752">1</xref>
<xref ref-type="aff" rid="aff2-1470320311414752">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hodroj</surname><given-names>Wassim</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311414752">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sakly</surname><given-names>Mohsen</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311414752">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Randon</surname><given-names>Jacques</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311414752">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bricca</surname><given-names>Giampiero</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311414752">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320311414752"><label>1</label>INSERM ERI-22, Agressions Vasculaires et Réponses Tissulaires, Université de Claude Bernard, Lyon I, France</aff>
<aff id="aff2-1470320311414752"><label>2</label>Université de Carthage. Unité de Physiologie Intégrée, Laboratoire de Pathologies Vasculaires, Faculté des Sciences de Bizerte, Tunisia</aff>
<author-notes>
<corresp id="corresp1-1470320311414752">Houcine Dab, Unité de Physiologie Intégrée, Laboratoire de Pathologies Vasculaires, Faculté des Sciences de Bizerte, Jarzouna 7021, Tunisia Email: <email>houcine.dab@fsb.rnu.tn</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>28</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The interactions between the effects of the sympathetic nervous system (SNS) and angiotensin II (ANG II) on vascular extracellular matrix (ECM) synthesis were determined in rats.</p>
<p>The mRNA and protein content of collagen I, collagen III and elastin in the abdominal aorta (AA) and femoral artery (FA) was investigated in Wistar–Kyoto rats treated for 5 weeks with guanethidine, a sympathoplegic, losartan, an ANG II AT1 receptor (AT1R) blocker, or both. The effects of noradrenaline (NE) and ANG II on collagen III and elastin mRNA, and the receptor involved, were tested in cultured vascular smooth muscle cells (VSMCs) in vitro.</p>
<p>Guanethidine increased collagen types I and III and decreased elastin, while losartan had an opposite effect, although without effect on collagen III. The combination of treatments abrogated changes induced by simple treatment with collagen I and elastin, but increased collagen III mRNA in AA and not in FA. NE stimulated collagen III mRNA via β receptors and elastin via α1 and α2 receptors. ANG II stimulated collagen III but inhibited elastin mRNA via AT1R.</p>
<p>Overall, SNS and ANG II exert opposite and antagonistic effects on major components of ECM in the vascular wall. This may be of relevance for the choice of a therapeutic strategy in vascular diseases.</p>
</abstract>
<kwd-group>
<kwd>Adrenergic receptor antagonist</kwd>
<kwd>angiotensin II AT1 receptor antagonist</kwd>
<kwd>aorta</kwd>
<kwd>collagen</kwd>
<kwd>elastin</kwd>
<kwd>femoral artery</kwd>
<kwd>noradrenaline</kwd>
<kwd>sympathectomy</kwd>
<kwd>vascular smooth muscle cells</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320311414752" sec-type="intro">
<title>Introduction</title>
<p>Extracellular matrix (ECM) is an essential component of pluricellular organisms, since it is the substratum secreted by cells to ‘condition’ their medium and the shape of the organ and organism. In the arterial wall, the ECM determines both structural properties such as shape and resistance and functional properties such as elasticity and blood flow.<sup><xref ref-type="bibr" rid="bibr1-1470320311414752">1</xref></sup> The ECM in the vascular wall is mostly composed of collagen types I and III<sup><xref ref-type="bibr" rid="bibr2-1470320311414752">2</xref></sup> and elastin embedded in mucopolysaccharides and adhesion molecules.</p>
<p>From a functional point of view, the ECM composition and turnover are regulated by genetic factors as well as blood pressure or shear stress, blood flow and neuroendocrine factors such as the renin–angiotensin system (RAS) and the sympathetic nervous system (SNS).<sup><xref ref-type="bibr" rid="bibr3-1470320311414752">3</xref>–<xref ref-type="bibr" rid="bibr5-1470320311414752">5</xref></sup> The effect of the SNS, and mostly of β-adrenergic stimulation, on ECM has been investigated in depth in the heart.<sup><xref ref-type="bibr" rid="bibr6-1470320311414752">6</xref></sup> However, much less is known about the role of the SNS in the regulation of ECM production in the arterial wall and vascular smooth muscle cells (VSMCs). Most published data indicate an increase of total collagen and a decrease in the amount of elastin in the arterial wall after sympathectomy.<sup><xref ref-type="bibr" rid="bibr7-1470320311414752">7</xref>,<xref ref-type="bibr" rid="bibr8-1470320311414752">8</xref></sup> On the other hand, the mechanisms involved in angiotensin II (ANG II) induced vascular remodelling have been investigated in much more detail. ANG II directly exerts its effects on VSMCs through angiotensin II type 1 receptors (AT1R) by activation of phospholipase C.<sup><xref ref-type="bibr" rid="bibr9-1470320311414752">9</xref>,<xref ref-type="bibr" rid="bibr10-1470320311414752">10</xref></sup> The activation of AT1R by ANG II induces growth and cell migration of VSMCs and modulates collagen synthesis by fibroblasts.<sup><xref ref-type="bibr" rid="bibr11-1470320311414752">11</xref></sup>
</p>
<p>Interactions between SNS and RAS have been investigated in the heart.<sup><xref ref-type="bibr" rid="bibr12-1470320311414752">12</xref>,<xref ref-type="bibr" rid="bibr13-1470320311414752">13</xref></sup> It was shown not only that ANG II could increase sympathetic outflow but also that it was required for isoproterenol induced heart hypertrophy. In the peripheral vessels, neuro-humoral interactions between the SNS and the RAS have been described. AT1R have been located on presynaptic terminals of perivascular sympathetic fibres and have been shown to activate and amplify noradrenaline release acting on blood vessels.<sup><xref ref-type="bibr" rid="bibr14-1470320311414752">14</xref>–<xref ref-type="bibr" rid="bibr16-1470320311414752">16</xref></sup> The AT1R blockade reduces NE release<sup><xref ref-type="bibr" rid="bibr14-1470320311414752">14</xref></sup> and enhances its uptake by SNS terminal axons.<sup><xref ref-type="bibr" rid="bibr17-1470320311414752">17</xref></sup> However, very few studies have described the interactions between the two systems in the vascular bed,<sup><xref ref-type="bibr" rid="bibr18-1470320311414752">18</xref>,<xref ref-type="bibr" rid="bibr19-1470320311414752">19</xref></sup> most often in pathological models.</p>
<p>The aim of this study was to clarify the interactions between the SNS and AT1R mediated ANG II effects on ECM production in the rat vasculature, centred on VSMCs. For this purpose, blockade of the SNS with guanethidine and of AT1R with losartan was performed alone or in combination to determine their respective contributions to ECM synthesis in the rat vessels. Primary cultures of VSMCs were used to identify the direct effects and the receptors involved.</p>
</sec>
<sec id="section2-1470320311414752" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1470320311414752">
<title>Animals</title>
<p>The animal protocols used for this study were approved by the University Animal Care and Use Committee of University of Claude Bernard, Lyon 1, France and were in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals.</p>
<p>Male Wistar–Kyoto rats (<italic>n</italic> = 32) were divided equally into four groups: a guanethidine treated group (GUA), a losartan treated group (LOS), a double treatment group (GUA+LOS) and a control group (CTRL). Rats were treated as previously described<sup><xref ref-type="bibr" rid="bibr13-1470320311414752">13</xref></sup> with guanethidine sulfate (50 mg/kg intraperitoneal injection, 5 days/week for 5 weeks) (Sigma, St Louis, MO, USA) for a sympathectomy. Losartan (20 mg/kg/day) was administered in drinking water for 5 weeks to block AT1R. The double treatment group received both guanethidine and losartan as described above for 5 weeks. The CTRL group received injections of saline for the same time period.</p>
<p>At the end of the treatment period, rats were deeply anaesthetised with pentobarbital (50 mg/kg i.p.). AA and FA were removed, carefully dissected from surrounding fat, immediately frozen in liquid nitrogen, and stored at −80°C.</p>
</sec>
<sec id="section4-1470320311414752">
<title>Blood pressure measurement</title>
<p>Systolic blood pressure (SBP) was measured weekly during the 5 weeks of treatment via a tail-cuff method.<sup><xref ref-type="bibr" rid="bibr20-1470320311414752">20</xref></sup>
</p>
</sec>
<sec id="section5-1470320311414752">
<title>Cell culture</title>
<p>VSMCs were obtained from AA samples with the explant technique (<italic>n</italic> = 6). Briefly, a strip of AA, carefully dissected by removing the adventitia, was cut into small fragments, which were placed in 25 cm<sup>2</sup> culture dishes in Dulbecco’s Modified Eagle’s Medium (DMEM) culture medium supplemented with fetal calf serum 10% (Promocell), glutamine 4.5 mM and antibiotic (streptomycin 0.1 g/l and penicillin 100 U/ml), maintained at 37°C and 5% CO<sub>2</sub>. Experiments were performed on cells from passages 2 to 4. VSMCs were checked by immunostaining of actin with anti-α-smooth muscle actin antibody (DAKO).<sup><xref ref-type="bibr" rid="bibr21-1470320311414752">21</xref>–<xref ref-type="bibr" rid="bibr23-1470320311414752">23</xref></sup> For the experiments, 100,000 cells were seeded in 12-well plates in their usual medium for at least 1 day. Twenty-four hours before the experiments, culture medium was changed to a basal VSMCs medium without fetal calf serum. On the day of the experiments, culture medium was replaced and the test substances were added at appropriate concentrations for 24 h as follows: noradrenaline (NE) (Fluka): 0, 10 nM, 100 nM or 1 µM with or without one of the specific adrenoreceptor antagonists (Sigma) βb (50 µM propranolol), αa1 (100 nM prazosin) and αa2 (10 µM yohimbine); ANG II: 0, 25 pM, 100 nM or 1 µM with or without 10 µM of losartan (Sigma), the specific AT1R antagonist.</p>
</sec>
<sec id="section6-1470320311414752">
<title>Total RNA extraction and real-time RT-PCR analysis</title>
<p>RNA was extracted from AA, FA and cultured aortic VSMCs using Trizol Reagent (Invitrogen, Carlsbad, CA) and treated with DNase (Deoxyribonuclease I, Amplification Grade, Invitrogen). The integrity of the purified RNA was verified by agarose gel electrophoresis followed by ethidium bromide staining. After DNase treatment, 5 µg of total RNA was reverse-transcripted with superscript II transcriptase (Invitrogen, France) using random hexamers as primers (pdN6; Amersham Biosciences, Piscataway, NJ). Real-time Reverse-transcriptase polymerase chain reaction (RT-PCR) for selected gene transcripts was performed using the resulting cDNA as template with a MyiQ thermal cycler (Bio-Rad Laboratories, Hercules, CA) with iQ SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) and the appropriate set of primers (Invitrogen, France) (<xref ref-type="table" rid="table1-1470320311414752">Table 1</xref>). Two-step RT-PCR real-time amplifications were carried out as follows: 3 min at 95° followed by 10 s at 95° and 45 s at 60°. For each cDNA sample, PCR was performed in duplicate. Dilutions of control template were used to generate the standard curves for each target gene. Cycle threshold values were calculated for the different products with Optical System Software v. 1.0 (Bio-Rad Laboratories). Expression levels obtained from the standard curves were normalised against 18S rRNA.</p>
<table-wrap id="table1-1470320311414752" position="float">
<label>Table 1.</label>
<caption>
<p>Sequences of primers used</p>
</caption>
<graphic alternate-form-of="table1-1470320311414752" xlink:href="10.1177_1470320311414752-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Sense</th>
<th align="left">Anti-sense</th>
<th align="left">Size (pb)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18S rRNA</td>
<td>AGTCGGCATCGTTTATGGTC</td>
<td>TGAGGCCATGATTAAGAGGG</td>
<td>190</td>
</tr>
<tr>
<td>Collagen I</td>
<td>CGAGACCCTTCTCACTCCTG</td>
<td>GGCATCCATAGTGCATCCTT</td>
<td>148</td>
</tr>
<tr>
<td>Collagen III</td>
<td>AGCTGGACCAAAAGGTGATG</td>
<td>GACCTCGTGCTCCAGTTAGC</td>
<td>162</td>
</tr>
<tr>
<td>Elastin</td>
<td>AGCTCCCTTGTTCTTGTGGA</td>
<td>GGTGTGCCTAGCCAGACAGT</td>
<td>122</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section7-1470320311414752">
<title>Protein extraction and western blotting</title>
<p>Protein extraction and western blotting were performed as previously described.<sup><xref ref-type="bibr" rid="bibr13-1470320311414752">13</xref></sup> We used mouse monoclonal IgG antibodies specific for collagen types I and III or elastin (1:2000) and βb-actin (1:5000). All antibodies were from Sigma. Immunoreactivity of proteins was visualised by chemiluminescent detection (ECL, Amersham, Buckinghamshire, UK). Pre-stained molecular weight markers (Sigma) were used to assess and to check the separation and transfer of the appropriate protein. Visualised proteins were scanned and optical density was measured with Scion image software. Values were normalised to β-actin assessed on the same membranes after stripping off the first reaction.</p>
</sec>
<sec id="section8-1470320311414752">
<title>Statistical analysis</title>
<p>Statistical comparisons between treated and control groups were performed using ANOVA test. Subsequent pair-wise comparisons were performed with the HSD Tukey test using Statistica software (statsoft, France). Results are expressed as mean ± standard error of the mean (SEM). <italic>p</italic> &lt; 0.05 is taken as a significant probability and <italic>n</italic> values indicate the number of replicates.</p>
</sec>
</sec>
<sec id="section9-1470320311414752" sec-type="results">
<title>Results</title>
<p>Control animals and those treated with losartan alone did not show anomalous behaviour. As expected, animals treated with guanethidine displayed ptosis as a consequence of chemical sympathectomy.<sup><xref ref-type="bibr" rid="bibr24-1470320311414752">24</xref></sup>
</p>
<p>The body weights were similar in the four groups at the end of the treatment period (<xref ref-type="table" rid="table2-1470320311414752">Table 2</xref>). SBP was similar after losartan and guanethdine treatment, and remain significantly lower then control animals. Those receiving the double treatment had significantly lower SBP than CTRL, GUA and LOS rats.</p>
<table-wrap id="table2-1470320311414752" position="float">
<label>Table 2.</label>
<caption>
<p>Body weight and blood pressure record at the end of the experiment</p>
</caption>
<graphic alternate-form-of="table2-1470320311414752" xlink:href="10.1177_1470320311414752-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">CTR</th>
<th align="left">GUA</th>
<th align="left">LOS</th>
<th align="left">GUA + LOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>462 ± 25</td>
<td>441 ± 24</td>
<td>468 ± 22</td>
<td>455 ± 22</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>136.4 ± 3.5</td>
<td>121.4 ± 2.9<sup><xref ref-type="table-fn" rid="table-fn1-1470320311414752">**</xref></sup>
</td>
<td>118.5 ± 2.4<sup><xref ref-type="table-fn" rid="table-fn1-1470320311414752">**</xref></sup>
</td>
<td>105.8 ± 1.2<sup><xref ref-type="table-fn" rid="table-fn1-1470320311414752">***ττ§§</xref></sup></td>
</tr>
<tr>
<td>Variation from CTRL (%)</td>
<td>0</td>
<td>11</td>
<td>13</td>
<td>22.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320311414752">
<p>Values are means ± SD. <sup>**</sup><italic>p</italic> &lt; 0.01, <sup>***</sup><italic>p</italic> &lt; 0.001 versus CTRL, ττ<italic>p</italic> &lt; 0.01 versus sympathectomy group, <sup>§§</sup><italic>p</italic> &lt; 0.01 versus losartan treated group. CTRL: control, GUA: sympathectomy group, GUA+LOS: double treatment group, LOS: losartan treated group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section10-1470320311414752">
<title>In vivo study</title>
<sec id="section11-1470320311414752">
<title>Abdominal aorta</title>
<p>Sympathectomy significantly increased mRNA levels of collagen I and collagen III (<italic>p</italic> &lt; 0.05), while significantly decreasing the amount of elastin mRNA (<italic>p</italic> &lt; 0.05). Losartan treatment decreased collagen I (<italic>p</italic> &lt; 0.05), had no effect on collagen III and increased elastin (<italic>p</italic> &lt; 0.05) versus CTRL. After combined treatment, mRNA levels of collagen I and elastin were still similar to CTRL, while collagen III mRNA was increased (<italic>p</italic> &lt; 0.05) (<xref ref-type="fig" rid="fig1-1470320311414752">Figure 1 A</xref> and <xref ref-type="fig" rid="fig1-1470320311414752">C</xref>).</p>
<fig id="fig1-1470320311414752" position="float">
<label>Figure 1.</label>
<caption>
<p>Quantitative real-time RT-PCR and western blotting analysis of collagen I, collagen III (A and B) and α-elastin (C and D) in aorta from control and treated rats. Values are presented as ratio of mRNA to 18S rRNA for Q-PCR and as ratio of protein content to β-actin for western blotting. Data are mean ± SEM, <italic>n</italic> = 8 in each group. *<italic>p</italic> &lt; 0.05 versus CTRL, τ<italic>p</italic> &lt; 0.05 versus sympathectomy group, <sup>§</sup><italic>p</italic> &lt; 0.05 versus losartan treated group. CTRL: control, GUA: sympathectomy group, GUA + LOS: double treatment group, LOS: losartan treated group.</p>
</caption>
<graphic xlink:href="10.1177_1470320311414752-fig1.tif"/>
</fig>
<p>There was a good correlation between mRNA and protein levels for all studied targets. Sympathectomy significantly enhanced collagen I and collagen III protein amounts (<italic>p</italic> &lt; 0.05) and reduced elastin protein (<italic>p</italic> &lt; 0.05). Losartan treatment significantly decreased collagen I and enhanced elastin (<italic>p</italic> &lt; 0.05) without affecting the amount of collagen III. Combined treatment significantly enhanced only collagen III protein expression (<italic>p</italic> &lt; 0.05) (<xref ref-type="fig" rid="fig1-1470320311414752">Figure 1 B</xref> and <xref ref-type="fig" rid="fig1-1470320311414752">D</xref>).</p>
</sec>
<sec id="section12-1470320311414752">
<title>Femoral artery</title>
<p>In control rats, in accordance of differences between conductance and resistance arteries our results indicate that ECM mRNA was more expressed in AA than in FA; thus, amounts of collagen I and collagen III mRNA, respectively, were about 19-fold and two-fold higher and elastin mRNA nine times more abundant in AA than in FA.</p>
<p>Similarly to AA, sympathectomy significantly increases the amounts of collagen I and collagen III mRNA (<italic>p</italic> &lt; 0.01), while decreasing the amount of elastin (<italic>p</italic> &lt; 0.05). Losartan treatment decreases collagen I (<italic>p</italic> &lt; 0.01) and increases elastin (<italic>p</italic> &lt; 0.01) without affecting collagen III. In the double treatment group, amounts of elastin, collagen I and collagen III mRNA were similar to CTRL (<xref ref-type="fig" rid="fig2-1470320311414752">Figure 2</xref>).</p>
<fig id="fig2-1470320311414752" position="float">
<label>Figure 2.</label>
<caption>
<p>Quantitative real-time RT-PCR of collagen III (A) and elastin (B) mRNA in the FA from control and treated rats. Q-PCR values are presented as ratio of mRNA to 18S rRNA. Data are mean ± SEM; <italic>n</italic> = 8 in each group. *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01 versus CTRL, τ<italic>p</italic> &lt; 0.05, ττ<italic>p</italic> &lt; 0.01 versus sympathectomy group, <sup>§</sup><italic>p</italic> &lt; 0.05, <sup>§§</sup><italic>p</italic> &lt; 0.01 versus losartan treated group. CTRL: control, GUA: sympathectomy group, GUA + LOS: double treatment group, LOS: losartan treated group.</p>
</caption>
<graphic xlink:href="10.1177_1470320311414752-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section13-1470320311414752">
<title>VSMCs stimulation</title>
<sec id="section14-1470320311414752">
<title>Basal characteristics of VSMCs</title>
<p>All cells present in culture were immunolabelled for αa-smooth muscle actin, demonstrating their nature as VSMCs (data not shown). In basal conditions without fetal calf serum and in the presence of physiological concentrations of insulin and glucose for 24 h, collagen III and elastin mRNA were detected in rat VSMCs.</p>
</sec>
</sec>
<sec id="section15-1470320311414752">
<title>Effect of NE on ECM gene expression</title>
<p>NE induced a dose dependent increase in collagen III and elastin mRNA levels. The increase was three-fold (<italic>p</italic> &lt; 0.01 and <italic>p</italic> &lt; 0.05, respectively) compared with untreated cells at the lowest NE concentration. At the highest doses of NE, elastin mRNA was more amplified than collagen III mRNA, by about eight-fold for elastin and more than five-fold for collagen III.</p>
<p>The effect of NE on mRNA levels for collagen III was abrogated completely by β blockade. NE-induced elastin mRNA expression was completely inhibited by α1 and α2 blockade and partially by β blockade (<xref ref-type="fig" rid="fig3-1470320311414752">Figure 3</xref>).</p>
<fig id="fig3-1470320311414752" position="float">
<label>Figure 3.</label>
<caption>
<p>Dose respfonse curves of 24 h NE stimulated VSMCs. Analysis of collagen III (A) and α-elastin (B) mRNA after three increasing doses of NE stimulation in the absence or presence of specific antagonists of adrenergic receptors: α1 (prazosin), α2 (yohimbine) and β (propranolol). Results are mean ± SEM. *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001 versus untreated cells, <sup>§</sup><italic>p</italic> &lt; 0.05, <sup>§§</sup><italic>p</italic> &lt; 0.01 versus NE. NE: noradrenaline.</p>
</caption>
<graphic xlink:href="10.1177_1470320311414752-fig3.tif"/>
</fig>
</sec>
<sec id="section16-1470320311414752">
<title>Effect of ANG II on ECM gene expression</title>
<p>ANG II treatment induced a linear dose dependent stimulation of collagen III mRNA level, while elastin mRNA was similarly reduced (about two-fold; <italic>p</italic> &lt; 0.05) at the three doses of ANG II (25 pM, 100 nM and 1 µM) (<xref ref-type="fig" rid="fig4-1470320311414752">Figure 4</xref>). Losartan completely inhibited ANG II-induced changes in expression of collagen III and elastin.</p>
<fig id="fig4-1470320311414752" position="float">
<label>Figure 4.</label>
<caption>
<p>Dose response curves of 24 h ANG II stimulated VSMCs. Analysis of collagen III (A) and α-elastin (B) mRNA after three doses of ANG II stimulation in the absence or presence of losartan, the specific antagonist of AT1R. mRNA content expressed as mean ± SEM. <sup>*</sup><italic>p</italic> &lt; 0.05, <sup>**</sup><italic>p</italic> &lt; 0.01 versus untreated cells, <sup>§</sup><italic>p</italic> &lt; 0.05, <sup>§§</sup><italic>p</italic> &lt; 0.01 versus ANG II. ANG II: angiotensin II.</p>
</caption>
<graphic xlink:href="10.1177_1470320311414752-fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="section17-1470320311414752" sec-type="discussion">
<title>Discussion</title>
<p>In the present study we showed that in vivo a sympathoplegic drug (guanethidine) and an ANG II AT1R antagonist (losartan), while both had similar and additive decreasing effects on blood pressure, had opposite effects on collagen and elastin expression, which antagonised each other when the two drugs were given in combination. These effects were present in both an elastic artery, AA, and a resistance vessel, the FA. In parallel, an in vitro study using primary VSMCs showed that, while all the effects of ANGII were mediated via AT1R, those of NE were mediated mainly by a-adrenoceptors and partially by β-adrenoceptors for elastin and through β-adrenoceptors for collagen III. Moreover, the close parallelism between mRNA and protein levels for the three examined ECM components in the three treated groups indicates that protein changes are directly related to their respective mRNA, and thus that regulation takes place at the transcriptional level.</p>
<p>In this study we assessed interaction between SNS and ANG II through AT1R but not ATR2. Therefore we have not tested AT2R antagonists, since AT1R has been well documented as the main ANG II receptor in several tissues such as vessel wall, heart and adrenal gland.<sup><xref ref-type="bibr" rid="bibr25-1470320311414752">25</xref></sup> Moreover, AT2R is unequally expressed in tissues like brain, heart and vessels and is only slightly expressed in blood vessels compared with other tissues. Furthermore, in the vascular bed it has been demonstrated that AT2R expression was not constant during embryonic development and in the neonate, whereas the AT1R in aorta is expressed at relatively constant levels from the first embryonic development to the adult stage,<sup><xref ref-type="bibr" rid="bibr26-1470320311414752">26</xref>,<xref ref-type="bibr" rid="bibr27-1470320311414752">27</xref></sup> and AT2R expression declines rapidly after birth.<sup><xref ref-type="bibr" rid="bibr28-1470320311414752">28</xref></sup> Thus, previous investigation has shown a higher level of AT2R mRNA expression in the outer medial–adventitial region, which persists after birth in the neonate, but completely disappears at 22 days after birth.<sup><xref ref-type="bibr" rid="bibr29-1470320311414752">29</xref></sup> As mentioned above, there is much evidence that ANG II acts only through AT1R in aortic cells of adult rats.</p>
<p>Interaction between the SNS and ANG II has been demonstrated by functional studies. Thus ANG II stimulates NE release from the SNS through AT1R expressed in sympathetic fibres coursing the blood vessels (presynaptic receptors) and in VSMCs.<sup><xref ref-type="bibr" rid="bibr30-1470320311414752">30</xref></sup> The use of a specific antagonist of AT1R lowers NE release<sup><xref ref-type="bibr" rid="bibr15-1470320311414752">15</xref></sup> and enhances its uptake by SNS terminal axons.<sup><xref ref-type="bibr" rid="bibr17-1470320311414752">17</xref></sup> Therefore ANG II can act indirectly via SNS. This has been termed the sympathostimulator pathway.<sup><xref ref-type="bibr" rid="bibr12-1470320311414752">12</xref></sup>
</p>
<p>Based on the literature, we hypothesise that ANG II acts in two ways to influence the local ECM synthesis: first by acting directly on the vascular wall via AT1R, and second via the sympathostimulator pathway.</p>
<p>To describe the crosslink between the two modes of action of ANG II, we proposed that: 1) sympathectomy induces elimination of SNS and thus ANG II action by the sympathostimulator pathway. In this condition, ANG II remains freely accessible only to AT1R on vessel tissue; 2) the combination of sympathectomy and AT1R blockade with losartan allows the action of ANG II mediated via its AT1R expressed in vessels cells (direct pathway) to be examined; 3) in the losartan treated group, losartan induces blockage of AT1R in both presynaptic sympathetic fibres and vessel tissue. The blockage of AT1R in SNS reduces noradrenaline (NE) release and enhances its uptake.<sup><xref ref-type="bibr" rid="bibr17-1470320311414752">17</xref></sup> The sympathostimulator pathway (indirect pathway) could be determined by comparison of the three experiments.</p>
<p>ECM is not simply an inert supporting network, but, rather, comprises an active and dynamic structure that has a fundamental role in the regulation of cardiovascular function in normal and pathological conditions. Abnormal synthesis or excessive reduction of ECM leading to cardiovascular diseases has been associated with hypertension, which is under the influence of SNS and ANG II.<sup><xref ref-type="bibr" rid="bibr31-1470320311414752">31</xref></sup> Type I and III collagens represent the major ECM components. In our study we have investigated the effect of SNS and ANG II on the two collagen types in vivo, but only collagen III was investigated in an in vitro study, for two reasons. First, we found that the two collagen types have approximately the same profiles of changes after all treatments, and to abridge the experimental procedure we chose to work only with collagen III in our in vitro study. Second, it has been established that collagen III is relatively more abundant in tissues subjected to periodic stress, such as the vasculature, and participates in the tridimensional organisation of type I collagen networks, and that only mutations in collagen III are associated with vascular diseases (for review see Arteaga-Solis et al.<sup><xref ref-type="bibr" rid="bibr32-1470320311414752">32</xref></sup>).</p>
<p>Paradoxically, while in vivo collagen III mRNA and also collagen I mRNA and protein levels were enhanced by sympathectomy, NE was still a potent stimulator of collagen III expression in isolated cells. These results are in accordance with previous reports.<sup><xref ref-type="bibr" rid="bibr7-1470320311414752">7</xref>,<xref ref-type="bibr" rid="bibr33-1470320311414752">33</xref>–<xref ref-type="bibr" rid="bibr35-1470320311414752">35</xref></sup> This discrepancy may be related to an in vivo ANG II-induced stimulation response. From our in vivo study, ANG II seems to stimulate directly, via AT1R, the gene expression of collagen I in AA and of both collagen I and III in FA. Along with this hypothesis, in our experimental model, guanethidine, which induces destruction of sympathetic perivascular fibres,<sup><xref ref-type="bibr" rid="bibr36-1470320311414752">36</xref></sup> most likely also eliminates the interaction of ANG II with sympathetic nerve terminals in the two sympathectomy groups (GUA and GUA+LOS groups). The increased synthesis of collagen seen in the GUA group was abolished or reduced by a combination with AT1R blockade (GUA+LOS group).</p>
<p>Based on our animal experiments, ANG II does not seem to be directly involved in the stimulation of the gene expression of collagen III in AA, since AT1R blockade was unable to reduce this level with or without sympathectomy. It has been reported that the stimulatory effect of ANG II depends on the type of collagen in human VSMCs, collagen V being more stimulated than collagen I and III.<sup><xref ref-type="bibr" rid="bibr37-1470320311414752">37</xref></sup> The increased collagen III seen in the GUA group is not reduced by AT1R blockade in LOS+GUA. These in vivo results may appear paradoxical when compared with in vitro data showing a strong stimulatory effect of ANG II on collagen III. One explanation is that, in contrast to collagen I, endogenous levels of ANG II induce only a weak stimulation of gene expression of collagen III in large arteries in vivo, and thus AT1R blockade was swamped by other stimulator factors such as endothelin.</p>
<p>Elastin mRNA and protein levels were differentially regulated by losartan and guanethidine, exerting opposite and antagonistic effects. Interestingly, our results suggest that ANG II inhibits directly via AT1R elastin gene expression, since the reduced level of elastin mRNA seen in the GUA group was blunted by AT1R blockage in the GUA+LOS group. SNS stimulates this level, since the stimulatory effect of losartan was reduced when associated with sympathectomy. In accordance with in vivo study, NE enhances elastin mRNA via α1 and α2-adrenergic receptors, and partially also by β-adrenergic receptors. Thus, ANG II may play a double role in elastin mRNA synthesis, by mediating a direct inhibition via AT1R on vascular smooth muscle cells and possibly by an indirect stimulation via potentiation of NE release from the SNS.</p>
<p>Interestingly, we found that NE-induced stimulation of collagen III and elastin expression was mediated differently by α and β-adrenergic receptors. It is, therefore, very likely that collagen and elastin mRNA expression had different intracellular transduction signal pathways, an aspect that warrants further investigation, since no previous reports have discussed this finding in rat aorta under normal conditions.</p>
<p>In our study there was no correlation between elastin expression and SBP changes in the three treated groups. Elastin was seen to increase or to reduce when SBP was reduced. However, in the case of collagen expression, the study raises the question of distinction between direct sympathetic and ANG II action on collagen expression and that induced by haemodynamic factors. It has been established that RAS plays an important role in the pathogenesis of vascular hypertrophy and arterial stiffness mainly through ANG II, which is involved in the development of hypertension by increasing the collagen content of the arterial wall, thickening and fibrotic remodelling, resulting in increased thickness and stiffening,<sup><xref ref-type="bibr" rid="bibr38-1470320311414752">38</xref>,<xref ref-type="bibr" rid="bibr39-1470320311414752">39</xref></sup> and the use of ANG II antagonists provides prevention of the damaging effects of hypertension on the arterial wall.<sup><xref ref-type="bibr" rid="bibr40-1470320311414752">40</xref></sup> These observations agree with our present data, since we found that losartan treatment diminished blood pressure, which is correlated with the profiles of collagen changes. On the other hand, previous investigations in heart and vessels have advanced some arguments that work against direct involvement of blood pressure in cardiovascular fibrosis.<sup><xref ref-type="bibr" rid="bibr41-1470320311414752">41</xref>–<xref ref-type="bibr" rid="bibr43-1470320311414752">43</xref></sup> Moreover, studies by Weber and co-workers have shown that myocardial fibrosis is not related to haemodynamic workload,<sup><xref ref-type="bibr" rid="bibr42-1470320311414752">42</xref></sup> which is closely associated with arterial pressure.<sup><xref ref-type="bibr" rid="bibr44-1470320311414752">44</xref></sup>
</p>
<p>ECM proteins are mostly regulated by the activity of a set of proteins such as matrix metalloproteinase (MMP). MMPs constitute a tightly regulated family of zinc dependent endopeptidases that degrade most components of the ECM and basement membrane, and can also function in many other proteolytic processes.<sup><xref ref-type="bibr" rid="bibr45-1470320311414752">45</xref></sup> The effect of each treatment presented in this study can be related either to imbalance of synthesis or/and to proteolysis by MMPs. In this context, we have tested in previous studies the effect of the three treatments on MMP and ECM expression in heart,<sup><xref ref-type="bibr" rid="bibr13-1470320311414752">13</xref>,<xref ref-type="bibr" rid="bibr46-1470320311414752">46</xref></sup> and have described the existence of a difference in relative amounts of mRNA and protein levels of ECM, with usually a higher level of protein than mRNA after the same three treatments used in this study. This observation was attributed to the posttranslational regulation of ECM proteins assisted by MMP, since we found that the synthesis and enzymatic activity of MMPs were decreased in the three treated groups.</p>
<p>Accumulation of interstitial collagen contributes to increased arterial stiffness,<sup><xref ref-type="bibr" rid="bibr47-1470320311414752">47</xref></sup> and its excessive reduction is a structural feature of vascular diseases leading to the fragility and rupture of atheromatous plaque or to the development of aneurysms.<sup><xref ref-type="bibr" rid="bibr48-1470320311414752">48</xref></sup> Altogether, our results help elucidate the interactions between these two systems in the regulation of vascular ECM production, as shown in <xref ref-type="fig" rid="fig5-1470320311414752">Figure 5</xref>. The inhibition of SNS or ANG II separately has been widely used to reduce cardiovascular mortality and morbidity. Therefore, comparisons have made between the effects of adrenergic antagonists and AT1R antagonists,<sup><xref ref-type="bibr" rid="bibr49-1470320311414752">49</xref></sup> but there has been less investigation of combined treatments.</p>
<fig id="fig5-1470320311414752" position="float">
<label>Figure 5.</label>
<caption>
<p>Schematic illustration of interaction between effects of SNS and ANG II on ECM expression: collagen I andf III and elastin in arterial smooth muscle cells. Black arrows: SNS-mediated action. Grey arrows: ANG II-mediated action, indirectly via SNS or directly via AT1R. The blockage of AT1R reduces the liberation of NE from SNS. When SNS is inhibited, ANG II can stimulate directly via AT1R collagen synthesis, leading to the increase of collagen protein. ANG II seems to stimulate collagen III mRNA moderately, and the blockage of its AT1R remains insufficient to reduce the level of this collagen, perhaps because of other stimulator systems such as endothelin that are activated when activity of SNS is reduced. ANG II exerts antagonistic action on gene expression of elastin, stimulation via SNS and an inhibition directly via AT1R. ANG II: angiotensin II, AT1R: angiotensin II AT1 receptor, ECM: extracellular matrix, NE: noradrenaline, SNS: sympathetic nervous system.</p>
</caption>
<graphic xlink:href="10.1177_1470320311414752-fig5.tif"/>
</fig>
<p>In conclusion, the present study allows a comparison between the effect of simple and combined treatments on expression of the major actors on vascular ECM remodelling, and demonstrates opposing effects of ANG II and SNS on ECM synthesis and a compensatory effect of combined treatments on changes of ECM expression induced by simple inhibition of ANG II and SNS, which are widely used in treatment of cardiovascular diseases. Moreover, in our previous study46 we demonstrated that combined treatment was more efficient than simple treatment for reducing the expression of MMP in heart. The combined treatment may be useful as a new therapeutic approach for better prevention and treatment of cardiovascular disorders, and needs to be investigated in depth.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<p>The authors declare that there is no conflict of interest.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>We wish to thank the association ‘Autour de Williams’ for their participation in the financing of reagents used in our experiments. Houcine Dab received a grant from the Ministry of Higher Education, Scientific Research and Technology (Tunisia) to work on this study.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311414752">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Humphrey</surname><given-names>JD</given-names></name>
</person-group>. <article-title>Vascular adaptation and mechanical homeostasis at tissue, cellular, and sub-cellular levels</article-title>. <source>Cell Biochem Biophys</source> <year>2008</year>; <volume>50</volume>: <fpage>53</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr2-1470320311414752">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Velleman</surname><given-names>SG</given-names></name>
<name><surname>McCormick</surname><given-names>RJ</given-names></name>
<name><surname>Ely</surname><given-names>D</given-names></name>
<name><surname>Jarrold</surname><given-names>BB</given-names></name>
<name><surname>Patterson</surname><given-names>RA</given-names></name>
<name><surname>Scott</surname><given-names>CB</given-names></name><etal/>
</person-group>. <article-title>Collagen characteristics and organization during the progression of cholesterol-induced atherosclerosis in Japanese quail</article-title>. <source>Exp Biol Med (Maywood)</source> <year>2001</year>; <volume>226</volume>: <fpage>328</fpage>–<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr3-1470320311414752">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brouwers-Ceiler</surname><given-names>DL</given-names></name>
<name><surname>Nelissen-Vrancken</surname><given-names>HJ</given-names></name>
<name><surname>Smits</surname><given-names>JF</given-names></name>
<name><surname>De Mey</surname><given-names>JG</given-names></name>
</person-group>. <article-title>The influence of angiotensin II-induced increase in aortic wall mass on compliance in rats in vivo</article-title>. <source>Cardiovasc Res</source> <year>1997</year>; <volume>33</volume>: <fpage>478</fpage>–<lpage>484</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311414752">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Rourke</surname><given-names>J</given-names></name>
<name><surname>Jiang</surname><given-names>X</given-names></name>
<name><surname>Hao</surname><given-names>Z</given-names></name>
<name><surname>Cone</surname><given-names>RE</given-names></name>
<name><surname>Hand</surname><given-names>AR</given-names></name>
</person-group>. <article-title>Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature</article-title>. <source>J Neurosci Res</source> <year>2005</year>; <volume>79</volume>: <fpage>727</fpage>–<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311414752">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miner</surname><given-names>EC</given-names></name>
<name><surname>Miller</surname><given-names>WL</given-names></name>
</person-group>. <article-title>A look between the cardiomyocytes: the extracellular matrix in heart failure</article-title>. <source>Mayo Clin Proc</source> <year>2006</year>; <volume>81</volume>: <fpage>71</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311414752">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Osadchii</surname><given-names>OE</given-names></name>
<name><surname>Woodiwiss</surname><given-names>AJ</given-names></name>
<name><surname>Deftereos</surname><given-names>D</given-names></name>
<name><surname>Norton</surname><given-names>GR</given-names></name>
</person-group>. <article-title>Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats</article-title>. <source>Pflugers Arch</source> <year>2007</year>; <volume>455</volume>: <fpage>251</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311414752">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fronek</surname><given-names>K</given-names></name>
<name><surname>Bloor</surname><given-names>CM</given-names></name>
<name><surname>Amiel</surname><given-names>D</given-names></name>
<name><surname>Chvapil</surname><given-names>M</given-names></name>
</person-group>. <article-title>Effect of long-term sympathectomy on the arterial wall in rabbits and rats</article-title>. <source>Exp Mol Pathol</source> <year>1978</year>; <volume>28</volume>: <fpage>279</fpage>–<lpage>289</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311414752">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lacolley</surname><given-names>P</given-names></name>
<name><surname>Glaser</surname><given-names>E</given-names></name>
<name><surname>Challande</surname><given-names>P</given-names></name>
<name><surname>Boutouyrie</surname><given-names>P</given-names></name>
<name><surname>Mignot</surname><given-names>JP</given-names></name>
<name><surname>Duriez</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Structural changes and in situ aortic pressure-diameter relationship in long-term chemical-sympathectomized rats</article-title>. <source>Am J Physiol</source> <year>1995</year>; <volume>269</volume>: <fpage>H407</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311414752">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balakrishnan</surname><given-names>SM</given-names></name>
<name><surname>Wang</surname><given-names>HD</given-names></name>
<name><surname>Gopalakrishnan</surname><given-names>V</given-names></name>
<name><surname>Wilson</surname><given-names>TW</given-names></name>
<name><surname>McNeill</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Effect of an endothelin antagonist on hemodynamic responses to angiotensin II</article-title>. <source>Hypertension</source> <year>1996</year>; <volume>28</volume>: <fpage>806</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311414752">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>d’Uscio</surname><given-names>LV</given-names></name>
<name><surname>Shaw</surname><given-names>S</given-names></name>
<name><surname>Barton</surname><given-names>M</given-names></name>
<name><surname>Lüscher</surname><given-names>TF</given-names></name>
</person-group>. <article-title>Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function</article-title>. <source>Hypertension</source> <year>1998</year>; <volume>31</volume>: <fpage>1305</fpage>–<lpage>1310</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311414752">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fyhrquist</surname><given-names>F</given-names></name>
<name><surname>Metsärinne</surname><given-names>K</given-names></name>
<name><surname>Tikkanen</surname><given-names>I</given-names></name>
</person-group>. <article-title>Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders</article-title>. <source>J Hum Hypertens</source> <year>1995</year>; <volume>9</volume> <supplement>Suppl 5</supplement>: <fpage>S19</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311414752">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zucker</surname><given-names>IH</given-names></name>
<name><surname>Wang</surname><given-names>W</given-names></name>
<name><surname>Pliquett</surname><given-names>RU</given-names></name>
<name><surname>Liu</surname><given-names>JL</given-names></name>
<name><surname>Patel</surname><given-names>KP</given-names></name>
</person-group>. <article-title>The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training</article-title>. <source>Ann N Y Acad Sci</source> <year>2001</year>; <volume>940</volume>: <fpage>431</fpage>–<lpage>443</lpage>.</citation>
</ref>
<ref id="bibr13-1470320311414752">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dab</surname><given-names>H</given-names></name>
<name><surname>Hachani</surname><given-names>R</given-names></name>
<name><surname>Hodroj</surname><given-names>W</given-names></name>
<name><surname>Sakly</surname><given-names>M</given-names></name>
<name><surname>Bricca</surname><given-names>G</given-names></name>
<name><surname>Kacem</surname><given-names>K</given-names></name>
</person-group>. <article-title>Differential control of collagen synthesis by the sympathetic and renin-angiotensin systems in the rat left ventricle</article-title>. <source>Auton Neurosci</source> <year>2009</year>; <volume>151</volume>: <fpage>106</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311414752">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cox</surname><given-names>SL</given-names></name>
<name><surname>Ben</surname><given-names>A</given-names></name>
<name><surname>Story</surname><given-names>DF</given-names></name>
<name><surname>Ziogas</surname><given-names>J</given-names></name>
</person-group>. <article-title>Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites</article-title>. <source>Br J Pharmacol</source> <year>1995</year>; <volume>114</volume>: <fpage>1057</fpage>–<lpage>1063</lpage>.</citation>
</ref>
<ref id="bibr15-1470320311414752">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dendorfer</surname><given-names>A</given-names></name>
<name><surname>Raasch</surname><given-names>W</given-names></name>
<name><surname>Tempel</surname><given-names>K</given-names></name>
<name><surname>Dominiak</surname><given-names>P</given-names></name>
</person-group>. <article-title>Interactions between the renin-angiotensin system (RAS) and the sympathetic system</article-title>. <source>Basic Res Cardiol</source> <year>1998</year>; <volume>93</volume>: <fpage>24</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr16-1470320311414752">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balt</surname><given-names>JC</given-names></name>
<name><surname>Mathy</surname><given-names>MJ</given-names></name>
<name><surname>Nap</surname><given-names>A</given-names></name>
<name><surname>Pfaffendorf</surname><given-names>M</given-names></name>
<name><surname>van Zwieten</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery</article-title>. <source>J Cardiovasc Pharmacol</source> <year>2001</year>; <volume>38</volume>: <fpage>141</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr17-1470320311414752">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raasch</surname><given-names>W</given-names></name>
<name><surname>Dominiak</surname><given-names>P</given-names></name>
<name><surname>Ziegler</surname><given-names>A</given-names></name>
<name><surname>Dendorfer</surname><given-names>A</given-names></name>
</person-group>. <article-title>Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation</article-title>. <source>Hypertension</source> <year>2004</year>; <volume>44</volume>: <fpage>346</fpage>–<lpage>351</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311414752">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hilgers</surname><given-names>KF</given-names></name>
<name><surname>Veelken</surname><given-names>R</given-names></name>
<name><surname>Rupprecht</surname><given-names>G</given-names></name>
<name><surname>Reeh</surname><given-names>PW</given-names></name>
<name><surname>Luft</surname><given-names>FC</given-names></name>
<name><surname>Mann</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Angiotensin II facilitates sympathetic transmission in rat hind limb circulation</article-title>. <source>Hypertension</source> <year>1993</year>; <volume>21</volume>: <fpage>322</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr19-1470320311414752">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wang</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Spinetti</surname><given-names>G</given-names></name>
<name><surname>Jiang</surname><given-names>LQ</given-names></name>
<name><surname>Monticone</surname><given-names>R</given-names></name>
<name><surname>Zhao</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats</article-title>. <source>Am J Pathol</source> <year>2005</year>; <volume>167</volume>: <fpage>1429</fpage>–<lpage>1442</lpage>.</citation>
</ref>
<ref id="bibr20-1470320311414752">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cerutti</surname><given-names>C</given-names></name>
<name><surname>Kurdi</surname><given-names>M</given-names></name>
<name><surname>Bricca</surname><given-names>G</given-names></name>
<name><surname>Hodroj</surname><given-names>W</given-names></name>
<name><surname>Paultre</surname><given-names>C</given-names></name>
<name><surname>Randon</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Transcriptional alterations in the left ventricle of three hypertensive rat models</article-title>. <source>Physiol Genomics</source> <year>2006</year>; <volume>27</volume>: <fpage>295</fpage>–<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr21-1470320311414752">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rogler</surname><given-names>G</given-names></name>
<name><surname>Lackner</surname><given-names>KJ</given-names></name>
<name><surname>Schmitz</surname><given-names>G</given-names></name>
</person-group>. <article-title>Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro</article-title>. <source>Am J Cardiol</source> <year>1995</year>; <volume>76</volume>: <fpage>114A</fpage>–<lpage>116A</lpage>.</citation>
</ref>
<ref id="bibr22-1470320311414752">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hodroj</surname><given-names>W</given-names></name>
<name><surname>Legedz</surname><given-names>L</given-names></name>
<name><surname>Foudi</surname><given-names>N</given-names></name>
<name><surname>Cerutti</surname><given-names>C</given-names></name>
<name><surname>Bourdillon</surname><given-names>MC</given-names></name>
<name><surname>Feugier</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2007</year>; <volume>27</volume>: <fpage>525</fpage>–<lpage>531</lpage>.</citation>
</ref>
<ref id="bibr23-1470320311414752">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sroka</surname><given-names>IM</given-names></name>
<name><surname>Heiss</surname><given-names>EH</given-names></name>
<name><surname>Havlicek</surname><given-names>L</given-names></name>
<name><surname>Totzke</surname><given-names>F</given-names></name>
<name><surname>Aristei</surname><given-names>Y</given-names></name>
<name><surname>Pechan</surname><given-names>P</given-names></name><etal/>
</person-group>. <article-title>A novel roscovitine derivative potently induces G1-phase arrest in platelet-derived growth factor-BB-activated vascular smooth muscle cells</article-title>. <source>Mol Pharmacol</source> <year>2010</year>; <volume>77</volume>: <fpage>255</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr24-1470320311414752">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Supowit</surname><given-names>SC</given-names></name>
<name><surname>Ethridge</surname><given-names>RT</given-names></name>
<name><surname>Zhao</surname><given-names>H</given-names></name>
<name><surname>Katki</surname><given-names>KA</given-names></name>
<name><surname>Dipette</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats</article-title>. <source>Am J Physiol Heart Circ Physiol</source> <year>2005</year>; <volume>289</volume>: <fpage>H1169</fpage>–<lpage>H1175</lpage>.</citation>
</ref>
<ref id="bibr25-1470320311414752">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>PK</given-names></name>
<name><surname>Griendling</surname><given-names>KK</given-names></name>
</person-group>. <article-title>Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system</article-title>. <source>Am J Physiol Cell Physiol</source> <year>2007</year>; <volume>292</volume>: <fpage>C82</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr26-1470320311414752">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakajima</surname><given-names>M</given-names></name>
<name><surname>Hutchinson</surname><given-names>H</given-names></name>
<name><surname>Fujinaga</surname><given-names>M</given-names></name>
<name><surname>Hayashida</surname><given-names>W</given-names></name>
<name><surname>Morishita</surname><given-names>R</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer</article-title>. <source>Proc Natl Acad Sci U S A</source> <year>1995</year>; <volume>92</volume>: <fpage>10,663</fpage>–<lpage>10,667</lpage>.</citation>
</ref>
<ref id="bibr27-1470320311414752">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>H</given-names></name>
<name><surname>Horiuchi</surname><given-names>M</given-names></name>
<name><surname>Akishita</surname><given-names>M</given-names></name>
<name><surname>Dzau</surname><given-names>VJ</given-names></name>
</person-group>. <article-title>Regulation of vascular development and differentiation by angiotensin II type 2 receptor</article-title>. <source>Hypertension</source> <year>1997</year>; <volume>30</volume>: <fpage>470</fpage>.</citation>
</ref>
<ref id="bibr28-1470320311414752">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shanmugam</surname><given-names>S</given-names></name>
<name><surname>Corvol</surname><given-names>P</given-names></name>
<name><surname>Gasc</surname><given-names>J-M</given-names></name>
</person-group>. <article-title>Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat</article-title>. <source>Hypertension</source> <year>1996</year>; <volume>28</volume>: <fpage>91</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr29-1470320311414752">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horiuchi</surname><given-names>M</given-names></name>
<name><surname>Akishita</surname><given-names>M</given-names></name>
<name><surname>Dzau</surname><given-names>VJ</given-names></name>
</person-group>. <article-title>Recent progress in angiotensin II type 2 receptor research in the cardiovascular system</article-title>. <source>Hypertension</source> <year>1999</year>; <volume>33</volume>: <fpage>613</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr30-1470320311414752">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Timmermans</surname><given-names>PB</given-names></name>
<name><surname>Smith</surname><given-names>RD</given-names></name>
</person-group>. <article-title>The diversified pharmacology of angiotensin II-receptor blockade</article-title>. <source>Blood Press Suppl</source> <year>1996</year>; <volume>2</volume>: <fpage>53</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr31-1470320311414752">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Opie</surname><given-names>LH</given-names></name>
</person-group>. <article-title>The neuroendocrinology of congestive heart failure</article-title>. <source>Cardiovasc J S Afr</source> <year>2002</year>; <volume>13</volume>: <fpage>171</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr32-1470320311414752">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arteaga-Solis</surname><given-names>E</given-names></name>
<name><surname>Gayraud</surname><given-names>B</given-names></name>
<name><surname>Ramirez</surname><given-names>F</given-names></name>
</person-group>. <article-title>Elastic and collagenous networks in vascular diseases</article-title>. <source>Cell Struct Funct</source> <year>2000</year>; <volume>25</volume>: <fpage>69</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr33-1470320311414752">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lurie</surname><given-names>KG</given-names></name>
<name><surname>Bristow</surname><given-names>MR</given-names></name>
<name><surname>Minobe</surname><given-names>WA</given-names></name>
<name><surname>Masek</surname><given-names>M</given-names></name>
<name><surname>Billingham</surname><given-names>ME</given-names></name>
</person-group>. <article-title>6-Hydroxydopamine mediated cardiotoxicity in rabbits</article-title>. <source>Am J Cardiovasc Pathol</source> <year>1988</year>; <volume>2</volume>: <fpage>181</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr34-1470320311414752">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Facoetti</surname><given-names>A</given-names></name>
<name><surname>Fallarini</surname><given-names>S</given-names></name>
<name><surname>Miserere</surname><given-names>S</given-names></name>
<name><surname>Bertolotti</surname><given-names>A</given-names></name>
<name><surname>Ferrero</surname><given-names>I</given-names></name>
<name><surname>Tozzi</surname><given-names>R</given-names></name><etal/>
</person-group>. <article-title>Histochemical study of cardiac mast cells degranulation and collagen deposition: interaction with the cathecolaminergic system in the rat</article-title>. <source>Eur J Histochem</source> <year>2006</year>; <volume>50</volume>: <fpage>133</fpage>–<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr35-1470320311414752">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Callaghan</surname><given-names>CJ</given-names></name>
<name><surname>Williams</surname><given-names>B</given-names></name>
</person-group>. <article-title>The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation</article-title>. <source>J Hypertens</source> <year>2002</year>; <volume>20</volume>: <fpage>287</fpage>–<lpage>294</lpage>.</citation>
</ref>
<ref id="bibr36-1470320311414752">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heath</surname><given-names>JW</given-names></name>
<name><surname>Burnstock</surname><given-names>G</given-names></name>
</person-group>. <article-title>Selectivity of neuronal degeneration produced by chronic guanethidine treatment</article-title>. <source>J Neurocytol</source> <year>1977</year>; <volume>4</volume>: <fpage>397</fpage>–<lpage>405</lpage>.</citation>
</ref>
<ref id="bibr37-1470320311414752">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>H</given-names></name>
<name><surname>Suzuki</surname><given-names>H</given-names></name>
<name><surname>Tajima</surname><given-names>S</given-names></name>
<name><surname>Ogata</surname><given-names>Y</given-names></name>
<name><surname>Tominaga</surname><given-names>T</given-names></name>
<name><surname>Sato</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells</article-title>. <source>J Hypertens</source> <year>1991</year>; <volume>9</volume>: <fpage>17</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr38-1470320311414752">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Systolic hypertension, arterial stiffness, and vascular damage: role of the renin–angiotensin system</article-title>. <source>Blood Press Monit</source> <year>2000</year>; <volume>5</volume>(<supplement>Suppl 2</supplement>): <fpage>S7</fpage>–<lpage>S11</lpage>.</citation>
</ref>
<ref id="bibr39-1470320311414752">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name>
<name><surname>Shykoff</surname><given-names>BE</given-names></name>
</person-group>. <article-title>Arterial stiffness: clinical relevance, measurement, and treatment</article-title>. <source>Rev Cardiovasc Med</source> <year>2001</year>; <volume>2</volume>: <fpage>29</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr40-1470320311414752">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Volpe</surname><given-names>M</given-names></name>
</person-group>. <article-title>Treatment of systolic hypertension: spotlight on recent studies with angiotensin II antagonists</article-title>. <source>J Hum Hypertens</source> <year>2005</year>; <volume>19</volume>: <fpage>93</fpage>–<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr41-1470320311414752">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mazzolai</surname><given-names>L</given-names></name>
<name><surname>Nussberger</surname><given-names>J</given-names></name>
<name><surname>Aubert</surname><given-names>JF</given-names></name>
<name><surname>Brunner</surname><given-names>DB</given-names></name>
<name><surname>Gabbiani</surname><given-names>G</given-names></name>
<name><surname>Brunner</surname><given-names>HR</given-names></name><etal/>
</person-group>. <article-title>Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system</article-title>. <source>Hypertension</source> <year>1998</year>; <volume>31</volume>: <fpage>1324</fpage>–<lpage>1330</lpage>.</citation>
</ref>
<ref id="bibr42-1470320311414752">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weber</surname><given-names>KT</given-names></name>
<name><surname>Brilla</surname><given-names>CG</given-names></name>
<name><surname>Campbell</surname><given-names>SE</given-names></name>
<name><surname>Zhou</surname><given-names>G</given-names></name>
<name><surname>Matsubara</surname><given-names>L</given-names></name>
<name><surname>Guarda</surname><given-names>E</given-names></name>
</person-group>. <article-title>Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure</article-title>. <source>Blood Press</source> <year>1992</year>; <volume>1</volume>: <fpage>75</fpage>–<lpage>85</lpage>.</citation>
</ref>
<ref id="bibr43-1470320311414752">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brilla</surname><given-names>CG</given-names></name>
<name><surname>Rupp</surname><given-names>H</given-names></name>
<name><surname>Funck</surname><given-names>R</given-names></name>
<name><surname>Maisch</surname><given-names>B</given-names></name>
</person-group>. <article-title>The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure</article-title>. <source>Eur Heart J</source> <year>1995</year>; <volume>16</volume> <supplement>Suppl O</supplement>: <fpage>107</fpage>–<lpage>109</lpage>.</citation>
</ref>
<ref id="bibr44-1470320311414752">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuschnir</surname><given-names>E</given-names></name>
</person-group>. <article-title>The left ventricle and hemodynamic patterns in essential hypertension</article-title>. <source>Regul Pept</source> <year>2005</year>; <volume>128</volume>: <fpage>221</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr45-1470320311414752">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagase</surname><given-names>H</given-names></name>
<name><surname>Brew</surname><given-names>K</given-names></name>
</person-group>. <article-title>Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors</article-title>. <source>Biochem Soc Symp</source> <year>2003</year>; <volume>70</volume>: <fpage>201</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr46-1470320311414752">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dab</surname><given-names>H</given-names></name>
<name><surname>Hachani</surname><given-names>R</given-names></name>
<name><surname>Hodroj</surname><given-names>W</given-names></name>
<name><surname>Sakly</surname><given-names>M</given-names></name>
<name><surname>Bricca</surname><given-names>G</given-names></name>
<name><surname>Kacem</surname><given-names>K</given-names></name>
</person-group>. <article-title>Differential control of MMP and t-PA/PAI-1 expressions by sympathetic and renin-angiotensin systems in rat left ventricle</article-title>. <source>Auton Neurosci</source> <year>2009</year>; <volume>150</volume>: <fpage>27</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr47-1470320311414752">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ford</surname><given-names>CM</given-names></name>
<name><surname>Li</surname><given-names>S</given-names></name>
<name><surname>Pickering</surname><given-names>JG</given-names></name>
</person-group>. <article-title>Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1999</year>; <volume>19</volume>: <fpage>1843</fpage>–<lpage>1851</lpage>.</citation>
</ref>
<ref id="bibr48-1470320311414752">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adiguzel</surname><given-names>E</given-names></name>
<name><surname>Ahmad</surname><given-names>PJ</given-names></name>
<name><surname>Franco</surname><given-names>C</given-names></name>
<name><surname>Bendeck</surname><given-names>MP</given-names></name>
</person-group>. <article-title>Collagens in the progression and complications of atherosclerosis</article-title>. <source>Vasc Med</source> <year>2009</year>; <volume>14</volume>: <fpage>73</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr49-1470320311414752">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kizer</surname><given-names>JR</given-names></name>
<name><surname>Dahlöf</surname><given-names>B</given-names></name>
<name><surname>Kjeldsen</surname><given-names>SE</given-names></name>
<name><surname>Julius</surname><given-names>S</given-names></name>
<name><surname>Beevers</surname><given-names>G</given-names></name>
<name><surname>de Faire</surname><given-names>U</given-names></name><etal/>
</person-group>. <article-title>Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study</article-title>. <source>Hypertension</source> <year>2005</year>; <volume>45</volume>: <fpage>46</fpage>–<lpage>52</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>